Preferred Label : Modified Vaccinia Virus Ankara Expressing Flt3L/OX40L MQ710;
NCIt synonyms : MVAdeltaE5R-Flt3L-OX40L; rMVA Expressing Flt3L/OX40L MQ710; MVA Expressing Flt3L/OX40L MQ710;
NCIt definition : A recombinant, non-replicative, modified vaccinia virus Ankara (MVA) engineered with
the deletion of the vaccinia E5R gene and the expression of two membrane-anchored
transgenes, fms-like tyrosine kinase 3 ligand (Flt3L) and OX40 ligand (OX40L), with
potential immunostimulatory and antineoplastic activities. Upon intratumoral administration,
MVA expressing Flt3L/OX40L MQ710 is transduced into tumor cells and Flt3L and OX40L
are expressed. The recombinant MVA, with the deletion of the E5R gene, activates the
cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway and
increases type I interferon (IFN) production. Flt3L binds to the Flt3 tyrosine kinase
receptor and promotes Flt3 signaling, thereby expanding the population of antigen-presenting
dendritic cells (DCs). OX40L binds to and activates signaling pathways downstream
of its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4;
OX40), which is expressed on activated T-cells and regulatory T-cells (Tregs). This
causes depletion of OX40-expressing Tregs in the tumor microenvironment (TME) via
OX40L-OX40 interaction and is facilitated by the rMVA-induced type I IFN and IFN-I
receptor (IFNAR)-mediated signaling. This inhibits Treg-mediated suppression of effector
T-cells, induces the proliferation of memory and effector T-lymphocytes and increases
cytokine production. Altogether, MQ710 promotes immune activation and anti-tumor immune
responses.;
Molecule name : MQ 710; MQ-710;
NCI Metathesaurus CUI : CL1906514;
Origin ID : C199613;
concept_is_in_subset
- has_target
